上海皓元医药股份有限公司更正公告

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. has issued a correction to its 2024 annual report regarding the sales and procurement data of its major customers and suppliers, clarifying inaccuracies without affecting the overall financial status or operational results of the company [1][8]. Customer Analysis - The sales amount from the top five customers was corrected to 328.66 million yuan, accounting for 14.48% of the total annual sales, with no sales from related parties [6][8]. - New additions to the top five customers include Ying'en Biological Pharmaceutical (Suzhou) Co., Ltd., FC 2020 Limited and its affiliates, and Nanchong Tanyou Pharmaceutical Technology Co., Ltd. [2][3][4]. Supplier Analysis - The procurement amount from the top five suppliers was updated to 116.98 million yuan, representing 16.50% of the total annual procurement, with related party procurement amounting to 17.06 million yuan, or 2.41% of the total [5][8]. - Toronto Research Chemicals Inc. was identified as a new addition to the top five suppliers [6][8]. Additional Information - The company expressed apologies for any inconvenience caused to investors due to the correction and emphasized its commitment to improving the quality of information disclosure in future reports [8].